Could Adding Bortezomib Have Benefit for High-Risk Follicular Lymphoma?

The CALGB 50904 trial tested the addition of bortezomib to ofatumumab and bendamustine in patients with previously untreated high-risk follicular lymphoma.

Source: CancerNetwork - June 25, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news